Medlive Technology (02192.HK) Sets 26 Mar 2026 Board Meeting to Approve FY 2025 Results and Final Dividend
Bulletin Express
Mar 16
Medlive Technology Co., Ltd. (stock code: 02192.HK) announced that its board of directors will convene on 26 March 2026. The meeting’s primary agenda is to review and approve the consolidated financial results for the year ended 31 December 2025 and to consider the declaration of a final dividend, if any.
The announcement, dated 16 March 2026, was signed by Chairwoman and Chief Executive Officer Ms. Tian Liping. The current board comprises four executive directors—Ms. Tian Liping, Mr. Tian Lixin, Mr. Tian Lijun, and Ms. Zhou Xin—two non-executive directors—Mr. Eiji Tsuchiya and Mr. Kazutaka Kanairo—and three independent non-executive directors—Mr. Richard Yeh, Dr. Ma Jun, and Ms. Wang Shan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.